Ischemic Injury and Ischemic Preconditioning in Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00184821|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : April 5, 2007
In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short period of ischemia that protects against subsequent ischemic exercise). Annexin A5 scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that results from ischemic exercise.
The following hypotheses are tested:
- Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared with previously studied healthy volunteers.
- Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on the validity of hypothesis 2, the effect of short pharmacological interventions are studied on vulnerability to forearm ischemia/reperfusion injury in the absence or presence of local forearm ischemic preconditioning.
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus, Insulin-Dependent Ischemia-Reperfusion Injury||Procedure: Ischemic preconditioning Procedure: Forearm ischemic exercise Procedure: Annexin A5 scintigraphy Drug: Diazoxide Drug: glibenclamide Drug: adenosine|
All patients will be studied in supine position after an overnight fast, while plasma glucose levels are monitored. In the first 8 patients intravenous insulin is administered as needed, to reach target glucose levels between 5-7 mmol/l. Patients will be subjected to 10 minutes of forearm ischemia (non-dominant arm), combined with handgripping at 50% of maximal force until exhaustion. Upon reperfusion, Tc-99m-HYNIC-Annexin A5 will be injected intravenously. Targeting of annexin A5 to thenar muscle and forearm flexor muscle will be quantified as the percentage difference in radioactivity between experimental and control side. This procedure will be performed twice (randomized cross-over design), with at least 2 week interval, either with or without 10 minutes ischemia followed by 10 minutes of reperfusion prior to ischemic exercise.
Depending on the results of this study, substudies will be performed to study the effect of diazoxide (K-ATP channel opener, may mimic ischemic preconditioning), glibenclamide (K-ATP channel blocker, may inhibit ischemic preconditioning) or adenosine (infusion into brachial artery of non-dominant arm as a substitute for ischemic preconditioning).
|Study Type :||Observational|
|Enrollment :||20 participants|
|Observational Model:||Defined Population|
|Official Title:||Acute Local Ischemic Preconditioning in Patients With Type 1 Diabetes in Vivo|
|Study Start Date :||June 2004|
|Actual Study Completion Date :||May 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184821
|Clinical Research Centre Nijmegen; Radboud University Nijmegen Medical Centre|
|Nijmegen, Gelderland, Netherlands, 6500 HB|
|Study Chair:||Richard Engbersen, MD||Radboud University Nijmegen Medical Centre; department of Pharmacology-Toxicology|
|Study Chair:||Gerard Rongen, MD, PhD||Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology|
|Study Chair:||Wim Oyen, MD, PhD||Radboud University Nijmegen Medical Centre; Department of Nuclear Medicine|
|Study Chair:||Marc Mol, MD, PhD||Canisius Wilhelmina Ziekenhuis Nijmegen; Department of Internal Medicine|
|Principal Investigator:||Paul Smits, MD, PhD||Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology|
|Study Chair:||B. Bravenboer, MD, PhD||Catharina Hospital Eindhoven, Dept. of Internal Medicine|